Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
The minimal pharmacophore for silent agonism of the α7 nicotinic acetylcholine receptor.
Papke RL
,
Chojnacka K
,
Horenstein NA
.
???displayArticle.abstract???
The minimum pharmacophore for activation of the human α7 nicotinic acetylcholine receptor (nAChR) is the tetramethylammonium cation. Previous work demonstrated that larger quaternary ammonium compounds, such as diethyldimethylammonium or 1-methyl quinuclidine, were α7-selective partial agonists, but additional increase in the size of the ammonium cation or the quinuclidine N-alkyl group by a single carbon to an N-ethyl group led to a loss of efficacy for ion channel activation. We report that although such compounds are ineffective at inducing the normal channel open state, they nonetheless regulate the induction of specific conformational states normally considered downstream of channel activation. We synthesized several panels of quaternary ammonium nAChR ligands that systematically varied the size of the substituents bonded to the central positively charged nitrogen atom. In these molecular series, we found a correlation between the molecular volume of the ligand and/or charge density, and the receptor's preferred distribution among conformational states including the closed state, the active state, a nonconducting state that could be converted to an activated state by a positive allosteric modulator (PAM), and a PAM-insensitive nonconducting state. We hypothesize that the changes of molecular volume of an agonist's cationic core subtly impact interactions at the subunit interface constituting the orthosteric binding site in such a way as to regulate the probability of conversions among the conformational states. We define a new minimal pharmacophore for the class of compounds we have termed "silent agonists," which are able to induce allosteric modulator-dependent activation but not the normal activated state.
,
Correction to "The Minimal Pharmacophore for Silent Agonism of the α7 Nicotinic Acetylcholine Receptor".
2015, Pubmed
,
Correction to "The Minimal Pharmacophore for Silent Agonism of the α7 Nicotinic Acetylcholine Receptor".
2015,
Pubmed
Armstrong,
The inner quaternary ammonium ion receptor in potassium channels of the node of Ranvier.
1972,
Pubmed
Auerbach,
Desensitization of mouse nicotinic acetylcholine receptor channels. A two-gate mechanism.
1998,
Pubmed
Borovikova,
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin.
2000,
Pubmed
Calas,
Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts.
2000,
Pubmed
Carter,
Channel blocking properties of a series of nicotinic cholinergic agonists.
1993,
Pubmed
CHEN,
Pharmacology of 1,1-dimethyl-4-phenylpiperazinium iodide, a ganglion stimulating agent.
1951,
Pubmed
Chojnacka,
Synthesis and evaluation of a conditionally-silent agonist for the α7 nicotinic acetylcholine receptor.
2013,
Pubmed
,
Xenbase
Clark,
Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.
2014,
Pubmed
de Jonge,
The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation.
2007,
Pubmed
Freitas,
The antinociceptive effects of nicotinic receptors α7-positive allosteric modulators in murine acute and tonic pain models.
2013,
Pubmed
Gamal-Eldin,
Cucurbit[7]uril host-guest complexes and [2]pseudorotaxanes with N-methylpiperidinium, N-methylpyrrolidinium, and N-methylmorpholinium cations in aqueous solution.
2013,
Pubmed
Green,
hChAT: a tool for the chemoenzymatic generation of potential acetyl/butyrylcholinesterase inhibitors.
2009,
Pubmed
Halevi,
Conservation within the RIC-3 gene family. Effectors of mammalian nicotinic acetylcholine receptor expression.
2003,
Pubmed
,
Xenbase
Hibbs,
Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal alpha7 nicotinic acetylcholine receptor.
2009,
Pubmed
Horenstein,
Multiple pharmacophores for the selective activation of nicotinic alpha7-type acetylcholine receptors.
2008,
Pubmed
,
Xenbase
Ito,
Interaction between quaternary ammonium ions and dipeptides: positive anion allosteric effect.
2005,
Pubmed
Kabbani,
Are nicotinic acetylcholine receptors coupled to G proteins?
2013,
Pubmed
Papke,
An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype.
1996,
Pubmed
,
Xenbase
Papke,
Merging old and new perspectives on nicotinic acetylcholine receptors.
2014,
Pubmed
Papke,
Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.
2002,
Pubmed
,
Xenbase
Papke,
Estimation of both the potency and efficacy of alpha7 nAChR agonists from single-concentration responses.
2006,
Pubmed
,
Xenbase
Papke,
Tricks of perspective: insights and limitations to the study of macroscopic currents for the analysis of nAChR activation and desensitization.
2010,
Pubmed
,
Xenbase
Papke,
Working with OpusXpress: methods for high volume oocyte experiments.
2010,
Pubmed
,
Xenbase
Papke,
Relationships of agonist properties to the single channel kinetics of nicotinic acetylcholine receptors.
1988,
Pubmed
Papke,
Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine.
2009,
Pubmed
,
Xenbase
Paulo,
Proteomic analysis of an alpha7 nicotinic acetylcholine receptor interactome.
2009,
Pubmed
Pavlov,
Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis.
2007,
Pubmed
Pesti,
Kinetic properties and open probability of α7 nicotinic acetylcholine receptors.
2014,
Pubmed
Rosas-Ballina,
Cholinergic control of inflammation.
2009,
Pubmed
Rosas-Ballina,
The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE.
2009,
Pubmed
SHORT,
Sympathetic nervous system blocking agents. Investigation of ethyl-, hydroxyethyl-, vinyloxyethyl-, and propargyl-benzyldimethylammonium halides and related compounds.
1962,
Pubmed
Skok,
Editorial: To channel or not to channel? Functioning of nicotinic acetylcholine receptors in leukocytes.
2009,
Pubmed
Stokes,
Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.
2012,
Pubmed
,
Xenbase
Thomsen,
The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia.
2012,
Pubmed
van Westerloo,
The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice.
2006,
Pubmed
Williams,
Intrinsically low open probability of α7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures.
2012,
Pubmed
,
Xenbase
Williams,
Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.
2011,
Pubmed
Williams,
Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states.
2011,
Pubmed
,
Xenbase
Young,
Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
2008,
Pubmed
,
Xenbase
Zhang,
The structural mechanism of the Cys-loop receptor desensitization.
2013,
Pubmed
Zhong,
From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor.
1998,
Pubmed
